This point is particularly pertinent given the recent reports of low prevalence of control of LDL-C concentrations in patients with AAA in both the United States and the United Kingdom.25,26 In addition, this group of patients should be considered in trials evaluating novel treatments of lipid-lowering medications, such as CETP or PCSK9 inhibitors. Here, CETP is linked to triple-A syndrome.